Chronic kidney disease and reduced renal COX2 expression in xanthinuria: a case-control study Authors: Marie-Hélène Normand, François Gougeon, Naeem Bhojani, Mélanie Dieudé, Guillaume Bollée Published: 2026 ABSTRACT AbstractBackgroundXanthinuria is a rare inherited metabolic disorder caused by xanthine dehydrogenase (XDH) deficiency, leading to excessive urinary xanthine excretion. It is associated with kidney stones and, in exceptional cases, renal failure. To date, no kidney biopsy findings have been reported in cases of xanthinuria. We present the first documented biopsy from such a patient, revealing a reduction in cyclooxygenase-2 (COX2) expression.Case presentationA 38-year-old man of Afghan origin presented with flank pain and a staghorn calculus in the right kidney. Laboratory tests revealed impaired renal function with serum creatinine at 192 µmol/L. Percutaneous nephrolithotomy was performed to remove the stone, and infrared analysis confirmed its 100% xanthine composition. Genetic sequencing identified two pathogenic variants in the XDH gene, confirming type I xanthinuria. Despite stone removal, renal function progressively declined during the following months, with serum creatinine reaching 238 µmol/L and significant albuminuria. Imaging revealed no residual stones or atrophy of the right kidney, while the left kidney remained free of lithiasis. A biopsy of the left kidney demonstrated advanced chronic kidney disease with fibrosis, without crystal deposits or stones. As the etiology of nephropathy remained unclear, we assessed COX2 expression, an enzyme involved in prostaglandin synthesis, in the left kidney tissue. Compared with healthy controls and biopsies from other advanced chronic kidney disease cases, the xanthinuria biopsy showed considerably reduced tubular COX2 expression. The patient ultimately developed end-stage renal failure at age 41 and underwent successful kidney transplantation, achieving excellent graft function 32 months post-transplant.ConclusionsThis case provides the first histopathological evidence of chronic kidney disease in xanthinuria without crystal deposition and identifies reduced tubular COX2 expression as a potential pathogenic mechanism. These findings support hypotheses from animal models suggesting that xanthine dehydrogenase deficiency may impair prostaglandin synthesis, contributing to kidney fibrosis and possibly abnormal nephrogenesis. Further investigation of similar cases could improve our understanding of rare metabolic disorders and inform strategies to preserve kidney function.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12882-026-05079-6.Keywords: Xanthinuria, Xanthine dehydrogenase, Chronic kidney disease, Cyclooxygenase-2, Case report Background Xanthinuria (OMIM #278300) is a rare metabolic disease characterized by the excretion of large amounts of xanthine in the urine. Two forms of the disease sharing an identical clinical presentation have been identified. Type I is linked to a genetic deficiency in xanthine dehydrogenase (XDH) [1], whereas type II is caused by a mutation in the molybdenum cofactor sulfurase (MOCOS) gene [2]. Xanthinuria is associated with the occurrence of kidney stones, although some patients may remain asymptomatic. Xanthinuria can rarely lead to bilateral stone formation with subsequent urinary obstruction and acute renal failure, particularly in young children [3, 4]. Aside from these uncommon obstructive presentations, renal failure is not considered a typical feature of the disease, though longitudinal data on kidney function in patients with xanthinuria, especially adults, remain scarce. Only exceptional cases of chronic kidney disease or end‑stage renal failure have been reported in the absence of urolithiasis. One such case involved a 41‑year‑old man with severe hypouricemia who presented with end‑stage renal failure and bilaterally small kidneys without stones [5]. Another report described a woman who developed albuminuria at age 22 and progressed to end‑stage renal disease by age 47, with severe hypouricemia caused by a homozygous microdeletion in the XDH gene and no history of nephrolithiasis [6]. In both instances, the underlying mechanism of kidney injury could not be established due to the absence of renal biopsy. Renal failure in xanthinuria therefore appears to be extremely rare and has mainly been described in the context of urinary obstruction. Unlike adenine phosphoribosyltransferase (APRT) deficiency, another purine metabolism disorder in which crystal‑induced renal failure is well documented [7], crystal‑mediated renal injury has not been reported in xanthinuria. Overall, the links between XDH and chronic kidney disease (CKD) remain poorly characterized, as does the existence of specific mechanisms, if any, that could lead to renal damage. In a mouse model, animals carrying mutations in the XDH gene exhibited recessive renal failure and a marked decrease in tubular expression of cyclooxygenase-2 (COX2), an enzyme responsible for prostaglandin, which has been shown to play an essential role in renal development [8–11]. Taken together, these data suggest that XDH deficiency may decrease COX2 expression and promote renal dysplasia and fibrosis. However, whether these animal observations apply to human pathology remains unknown. To the best of our knowledge, there are no reports in the literature of kidney biopsies from patients with xanthinuria. Case presentation We report here the case of a 38-year-old man of Afghan origin who presented with a staghorn stone in his right kidney. His left kidney was pelvic but free of lithiasis or signs of atrophy. Renal function was impaired, with a serum creatinine level of 192 µmol/l (eGFR 37 ml/min/1.73m2), which medical history and non-invasive laboratory tests failed to explain. The patient underwent percutaneous nephrolithotomy, and infrared analysis showed that the stone was 100% xanthine. Next-generation sequencing of the MOCOS and XDH genes was later performed by Prevention Genetics (Marshfield, Wisconsin, USA) and revealed two mutations in the XDH gene (c.140dupG and c.2729 C > T), further confirming the diagnosis of xanthinuria. Uricemia was undetectable, as expected in this context. Over the following months after the urological procedure, kidney function continued to worsen, accompanied by high-grade albuminuria. Imaging showed the absence of residual stones and atrophy of the right kidney, sequelae of the obstruction. Fourteen months after the percutaneous nephrolithotomy, the serum creatinine level was 238 µmol/l (eGFR 28 ml/min/1.73m2), and urinary protein-to-creatinine ratio was 0.347 g/mmol. A biopsy of the left kidney was performed and revealed advanced kidney disease with diffuse glomerulosclerosis and tubulointerstitial fibrosis (Fig. 1A). The immunofluorescence study was negative, and, noteworthily, no crystals were observed in the renal parenchyma. Histopathologic evaluation of a xanthinuria patient with extensive renal fibrosis and reduced COX2 tubular expression. Masson’s trichrome staining and anti-COX2 immunohistochemistry staining of kidney biopsies from a type I xanthinuria patient (n = 1) compared to normal (n = 4), FSGS/IFTA (n = 4), glomerulosclerosis (n = 4) and diabetic nephropathy biopsies (n = 4). (A) Representative images of Masson’s trichrome-stained kidney biopsies (10X magnification). The xanthinuria and CKD biopsies present important renal glomerulosclerosis (B) and tubulointerstitial fibrosis (C) compared with healthy controls. (D) Representative images of kidney biopsy sections stained with anti-COX2 (10X magnification). Anti-COX2 immunohistochemical staining of the xanthinuria patient’s biopsy showed reduced COX2 tubular expression in contrast to normal and CKD biopsies (E). Data is presented as mean ± SEM. High power field (HPF). P values were calculated using one-way ANOVA tests (**P < 0.01 and ***P < 0.001) The cause of this nephropathy remained unclear. Inspired by data stemming from murine models of xanthinuria, we studied the renal expression of COX2 in the biopsy from our patient with xanthinuria compared with renal biopsies from healthy controls and CKD patients (Additional file 1). The latter had CKD at an advanced stage related to diabetic nephropathy, nonspecific focal segmental glomerulosclerosis (FSGS) and interstitial fibrosis tubular atrophy (IFTA) or glomerulosclerosis without a clearly identified cause other than hypertensive nephropathy. As in our index case of xanthinuria, CKD biopsies showed extensive fibrosis, affecting approximately 50% of the renal parenchyma (Fig. 1A-C). Across all groups, COX2 expression was primarily observed in proximal tubules, whereas COX2 expression in distal tubules was very weak (Additional file 2). Strikingly, COX2 tubular expression was stunted in the xanthinuria biopsy compared to normal and CKD biopsies (Fig. 1D, E). These observations corroborate previous findings by Piret et al. in a murine model of recessive renal failure associated with XDH nonsense mutations [8]. Unfortunately, our patient with xanthinuria reached end-stage renal failure at 41-year-old. Afterwards, the patient underwent renal transplantation with an excellent outcome and normal graft function 32 months post-transplantation, with a serum creatinine level of 93 µmol/l (eGFR 32 ml/min/1.73m2). Discussion and conclusions Here, we document the first renal biopsy for a patient diagnosed with xanthinuria. Kidney biopsy showed advanced glomerulosclerosis and fibrosis. In the absence of urinary obstruction and crystal deposits in the parenchyma, the cause of this nephropathy continued to be uncertain. Additionally, it remained unclear why our patient developed such severe disease when xanthinuria is not typically associated with renal failure. A key insight from this first investigation of a xanthinuria kidney biopsy is the markedly reduced tubular COX2 expression compared with both advanced CKD cases and healthy controls. This finding is consistent with previous animal studies linking XDH deficiency, reduced tubular COX2 expression, and the development of kidney fibrosis. Piret et al. reported a mouse model of recessive renal failure caused by XDH nonsense mutations, in which renal failure occurred in the absence of stones or crystalline deposits [8]. A prominent feature of this model was a marked decrease in tubular cyclooxygenase‑2 (COX2) expression, an enzyme essential for prostaglandin synthesis and renal development. Additional support comes from another model in which XOR‑/‑ mice also exhibited decreased COX2 expression and renal dysplasia with severe fibrosis [9]. Although both models ultimately disrupt xanthine oxidoreductase activity, they are considered distinct because XDH‑mutant mice harbor mutation‑specific loss of dehydrogenase function, whereas XOR⁻/⁻ mice completely lack the enzyme, abolishing both dehydrogenase and oxidase activities. Notably, this phenotype closely resembles the one observed in COX2‑deficient animals [10, 11]. Taken together, these data suggest that XDH deficiency may impair kidney development via reduced COX2 expression. Our findings appear consistent with these mechanisms, and the severe renal failure that occurred in our patient could reflect the ultimate progression of renal dysplasia. However, our data do not allow us to determine whether xanthinuria might also contribute to renal fibrosis through mechanisms operating beyond renal development. COX2 expression in the adult kidney is essential for regulating blood pressure and renal blood flow and preserving medullary and interstitial integrity through anti-apoptotic mechanisms [12, 13]. The fact that only a minority of patients with XDH deficiency develop renal failure, and usually later in life, suggests that the renal phenotype associated with XDH deficiency is considerably milder in humans than in mice, for reasons that remain to be clarified. In humans, XDH deficiency may thus represent a susceptibility factor for chronic kidney disease, likely requiring additional, still unidentified, contributors. While our observations are mainly hypotheses generating, careful analysis of renal function and albuminuria in other patients with xanthinuria would be essential to elucidate the link with chronic kidney disease and understand its mechanisms. We hope that our work will encourage other nephrologists who encounter such exceptional observations to study them in depth. This, along with further studies in animal models, may lead to advances in our understanding of the mechanisms involved in rare diseases and to the acquisition of a better understanding of key determinants of kidney homeostasis. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1: Material and Methods, Detailed description of the participants, study design and immunohistochemistry protocol used in this study Supplementary Material 2: Tubular COX2 expression, Histological analysis of renal COX2 expression in distal and proximal tubules in biopsies of xanthinuria patient compared to healty controls and CKD patients Acknowledgements The authors would like to acknowledge the contribution of Véronique Barrès and Liliane Meunier from the molecular pathology core facility of the CHUM Research Center (CRCHUM). Abbreviations Xanthine dehydrogenase Molybdenum cofactor sulfurase Adenine phosphoribosyltransferase Chronic kidney disease Cyclooxygenase-2 Estimated glomerular filtration rate Focal segmental glomerulosclerosis Interstitial fibrosis tubular atrophy Author contributions GB and MD were responsible for the research idea and study design. MHN performed the histological examination of renal biopsies and was a major contributor in writing the manuscript. FG and NB corroborated MHN’s histological analysis. MD and GB were major contributors in writing the manuscript and provided supervision and mentorship. All authors substantially participated in the study design, drafted the manuscript, made revisions and approved the final manuscript. Funding The authors received financial support from the renal department of the Centre hospitalier de l’Université de Montréal (CHUM) for this work. Unrelated to this study, GB received honorary consulting fees from Novartis and Otsuka, GB participated in the advisory board of Otsuka on ADPKD and MD is the Director of Research Operations Medical Affairs and Innovation for Héma-Québec. Data availability The datasets generated and analyzed during this study are included within this article and its additional files. The patient’s pathogenic variant XDH c.140dupG was submitted to ClinVar (SCV007580262) and is associated with the aggregate record VCV000641114.20. The likely pathogenic XDH c.2729 C> T variant identified in this xanthinuria patient was submitted to ClinVar (SCV007580263) and is associated with the aggregate record VCV000783325.12. Declarations Ethics approval and consent to participate The study design was approved by the research ethics committee of the CRCHUM (21.020). All patients provided informed written consent, and the study was conducted in accordance with the Declaration of Helsinki. Clinical trial number: not applicable. Consent for publication Patient gave written informed consent for their personal and clinical details to be published in this study. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Mélanie Dieudé, Email: melanie.dieude@umontreal.ca. Guillaume Bollée, Email: guillaume.bollee.med@ssss.gouv.qc.ca. References Associated Data Supplementary Materials Supplementary Material 1: Material and Methods, Detailed description of the participants, study design and immunohistochemistry protocol used in this study Supplementary Material 2: Tubular COX2 expression, Histological analysis of renal COX2 expression in distal and proximal tubules in biopsies of xanthinuria patient compared to healty controls and CKD patients Data Availability Statement The datasets generated and analyzed during this study are included within this article and its additional files. The patient’s pathogenic variant XDH c.140dupG was submitted to ClinVar (SCV007580262) and is associated with the aggregate record VCV000641114.20. The likely pathogenic XDH c.2729 C> T variant identified in this xanthinuria patient was submitted to ClinVar (SCV007580263) and is associated with the aggregate record VCV000783325.12.